

# Acute generalized exanthematous pustulosis induced by iodinated contrast media: a case report

Maisa Alfalah,<sup>1</sup> Yara Alotaibi,<sup>2</sup> Atheer Alotaibi,<sup>3</sup> Raghad Alharthi<sup>1</sup>

<sup>1</sup>Dermatology Department, King Abdulaziz Medical City, Riyadh; <sup>2</sup>Imam Mohammed bin Saud Islamic University, Riyadh;

<sup>3</sup>College of Medicine, Almaarefa University, Riyadh, Saudi Arabia

## Abstract

Acute generalized exanthematous pustulosis (AGEP) is a rare pustular eruption commonly triggered by drugs. It is characterized by acute onset of pustules on erythematous-edematous skin and often presents with fever. This report describes AGEP following exposure to iodinated contrast media (ICM), specifically iobitridol, in a 68-year-old male with multiple comorbidities. The patient developed characteristic erythematous patches with pustules on the body after initial CT imaging with ICM for a prostate abscess. Histological findings and recurrence following re-exposure con-

firmed AGEP, which was attributed to ICM. This case emphasizes the need for awareness of ICM as a potential trigger for AGEP. Management included topical steroids and antihistamines, resulting in a rapid recovery.

## Introduction

Acute generalized exanthematous pustulosis (AGEP) represents a severe and infrequent reaction pattern primarily associated with drugs, marked by the development of superficial pustules over erythematous-edematous skin, accompanied by an episode of fever, which regresses a few days after discontinuation of the trigger. AGEP is characterized by a rapid clinical progression, distinct histology, and unique morphology.<sup>1</sup> While the triggers are commonly linked to drug exposure, other potential triggers, including infections, spider bites, and contrast sensitivity, have been suggested. However, instances of occurrence after the administration of iodinated contrast media (ICM) are uncommon. These occurrences are typically associated with T-cell mediation. Contrast media containing iodine are administered to enhance visibility in medical imaging procedures such as X-rays and computed tomography (CT).<sup>2</sup> ICM-related delayed reactions are probably underreported because they are not adequately recognized. We present a case study illustrating AGEP in a patient after exposure to ICM.

## Case Report

A 68-year-old male with a history of diabetes mellitus, benign prostate hyperplasia, recurrent urinary tract infections, and previous gastric lymphoma treated with radiotherapy, presented with increased sputum production and dyspnea. An abdominal CT scan with iodinated intravenous contrast (iobitridol) identified a prostate abscess. Three days post-contrast, the patient developed generalized blanchable erythematous patches with scaling over the scalp, face, trunk (Figures 1 and 2), and extremities (Figures 3 and 4), along with pustules on the abdomen. Vital signs remained stable. There was no facial or limb edema, skin sloughing, bullae, erosions, mucosal involvement, or lymphadenopathy.

Laboratory findings revealed leukocytosis without renal or liver abnormalities. A drug chart was reviewed, and the likely triggers were identified as anidulafungin and contrast media. Histopathology of a skin biopsy showed subcorneal neutrophilic pustules and papillary dermal edema with mixed inflammatory cell infiltration, supporting a diagnosis of AGEP. Treatment included topical mometasone furoate 0.1% twice daily and oral antihistamines, leading to improvement. A second IV contrast CT scan led to a rash recurrence, confirming the ICM-induced AGEP diagnosis. The primary team was advised to avoid future ICM exposure unless necessary. Symptoms resolved within five days.

Correspondence: Atheer Alotaibi, College of Medicine, Almaarefa University, Al Nofouz, 11597, Riyadh, Saudi Arabia.

E-mail: dr.atheertu@gmail.com

Tel.: +966.550504941.

Key words: acute generalized exanthematous pustulosis; contrast media; iodinated contrast; drug reaction; pustular eruption.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient gave his written consent to use his personal data for the publication of this case report and any accompanying images.

Availability of data and materials: all data supporting the findings of this study are included in this case report. Additional details are available from the corresponding author upon reasonable request.

Received: 11 December 2024.

Accepted: 22 February 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Dermatology Reports 2025; 17:10217

doi:10.4081/dr.2025.10217

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Discussion

Contrast media-related AGEP is a rare phenomenon, often overlooked or misattributed due to the variable presentation and patients receiving multiple medications simultaneously, especially in those with multiple comorbidities. Medications are usually the first to be suspected, so proper recognition and management are crucial to prevent complications and ensure favorable outcomes.

O'Driscoll *et al.* described a similar case involving an 83-year-old woman who underwent contrast abdominal CT using iopamidol for the diagnosis of abdominal pain, leading to her developing AGEP twice due to the lack of recognition of ICM as a causative agent, and a third attack despite clear allergy labeling

in the patient's medical records.<sup>3</sup> Mizuta *et al.* reported a 56-year-old woman who experienced systemic erythematous eruptions after her first administration of iopamidol during radiologic examinations for an inferior thyroid artery aneurysm.<sup>4</sup> Sarre *et al.* reported a 53-year-old woman who developed a pruritic skin eruption with pustular lesions following an intra-articular injection of iodixanol for knee arthrography.<sup>5</sup> Kim *et al.* presented a case of a 27-year-old man with chronic renal failure who noticed a rash six hours after angiography with ioversol.<sup>6</sup> Hammerbeck *et al.* described an 84-year-old man undergoing chemotherapy for stage IV bladder cancer who developed a skin eruption following a pelvic CT scan with contrast.<sup>7</sup> De Groot *et al.* identified 93 drugs resulting in 259 positive patch tests among 248 patients with



**Figure 1.** Erythematous patches and pustules on the chest.



**Figure 3.** Red patches and scaly pustular eruption on the arm.



**Figure 2.** Extensive erythematous patches and scaling on the abdomen.



**Figure 4.** Erythematous scaling and pustules on the arm.

AGEP, with ICM accounting for 7.3% of these reactions, underscoring the association between these agents and AGEP.<sup>8</sup>

These cases highlight the recurrent and severe nature of AGEP linked to ICM and antibiotics, as seen in our patient. This underscores the importance of considering AGEP in the differential diagnosis of cutaneous reactions following contrast media administration, particularly given the limited literature on iobitridol-induced cutaneous responses, especially in patients with predisposing comorbidities. When patients are receiving multiple medications simultaneously, it is possible to mistakenly attribute the reaction to oral medications. In general, patch testing emerges as a valuable diagnostic tool in establishing the link between the reaction and ICM.<sup>4,9</sup> Clinicians should be vigilant in recognizing and managing this potentially serious adverse event to optimize patient care and outcomes. In our case, prompt discontinuation of the offending agent and initiation of appropriate therapy with topical steroids and antihistamines led to rapid resolution of symptoms. This case report describes a rare adverse event following iobitridol administration, which has been scarcely documented in the medical literature.

---

## Conclusions

This case illustrates a rare adverse reaction following iobitridol use, stressing the importance of recognizing AGEP as a potential ICM reaction. Prompt identification and management can optimize patient outcomes and prevent further exposure.

---

## References

1. Velter C, Schissler C, Moulinas C, et al. Acute generalized exanthematous pustulosis caused by an iodinated contrast radiocontrast medium for computed tomography arthrography of the knee. *Contact Dermatitis* 2017;76:371-3.
2. U.S. Food and Drug Administration. Iodinated Contrast Media (ICM). 2022. Available from: <https://www.fda.gov/drugs/information-drug-class/iodinated-contrast-media-icm>
3. O'Driscoll D, Foria V, Fityan A, et al. Accidental re-exposure causing repeated severe acute generalized exanthematous pustulosis. *Clin Exp Dermatol* 2019;44:927-9.
4. Mizuta T, Kasami S, Shigehara Y, et al. Acute generalized exanthematous pustulosis caused by iopamidol with recurrence on rechallenge with iopromide. *JAAD Case Rep* 2020;6:964-6.
5. Sarre ME, Mancel E, Drouet M, et al. Allergic contact dermatitis caused by cetearyl isononanoate in a sunscreen product. *Contact Dermatitis* 2017;76:357-8.
6. Kim SJ, Lee T, Lee YS, et al. Acute generalized exanthematous pustulosis caused by radiocontrast media. *Ann Allergy Asthma Immunol* 2010;105:492-3.
7. Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis: A case report. *Arch Dermatol* 2009;145:683-7.
8. de Groot AC. Results of patch testing in acute generalized exanthematous pustulosis (AGEP): A literature review. *Contact Dermatitis* 2022;87:119-41.
9. Tasker F, Fleming H, McNeill G, et al. Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. *Clin Exp Dermatol*